417 related articles for article (PubMed ID: 18794711)
61. Mapping the relationships between inflammatory bowel disease and comorbid diagnoses to identify disease associations.
Waljee AK; Noureldin M; Berinstein JA; Cohen-Mekelburg SA; Wallace BI; Cushing KC; Hanauer DA; Keeney-Bonthrone TP; Nallamothu B; Higgins PDR
Eur J Gastroenterol Hepatol; 2020 Oct; 32(10):1341-1347. PubMed ID: 32804850
[TBL] [Abstract][Full Text] [Related]
62. [Pyoderma gangrenosum associated with erythema nodosum and ulcerative colitis].
Vidal Pich E; Bianchi C; Bianchi O; Cuomo G
Med Cutan Ibero Lat Am; 1974; 2(6):425-32. PubMed ID: 4478909
[No Abstract] [Full Text] [Related]
63. [Dermatologic Manifestations in Inflammatory Bowel Disease].
Suh HY; Lee WJ; Na SY
Korean J Gastroenterol; 2019 May; 73(5):285-293. PubMed ID: 31132835
[TBL] [Abstract][Full Text] [Related]
64. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.
Wang J; Prenner J; Wang W; Sakuraba A; Hyman N; Dalal S; Hurst R; Cohen RD; Umanskiy K; Shogan BD; Alpert L; Rubin DT; Colwell J; Pekow J
Aliment Pharmacol Ther; 2020 Jun; 51(12):1365-1372. PubMed ID: 32383278
[TBL] [Abstract][Full Text] [Related]
65. Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes.
Jansen FM; Vavricka SR; den Broeder AA; de Jong EM; Hoentjen F; van Dop WA
United European Gastroenterol J; 2020 Nov; 8(9):1031-1044. PubMed ID: 32921269
[TBL] [Abstract][Full Text] [Related]
66. [Cutaneous manifestations with ulcerative colitis].
Arai S; Katsuoka K
Nihon Rinsho; 1999 Nov; 57(11):2571-4. PubMed ID: 10572433
[TBL] [Abstract][Full Text] [Related]
67. The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum.
Ashchyan HJ; Butler DC; Nelson CA; Noe MH; Tsiaras WG; Lockwood SJ; James WD; Micheletti RG; Rosenbach M; Mostaghimi A
JAMA Dermatol; 2018 Apr; 154(4):409-413. PubMed ID: 29450453
[TBL] [Abstract][Full Text] [Related]
68. A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease.
Annese V
Saudi J Med Med Sci; 2019; 7(2):66-73. PubMed ID: 31080385
[TBL] [Abstract][Full Text] [Related]
69. Psoriasis and erythema nodosum: two comorbidities of inflammatory bowel diseases.
De Simone C; Sollena P; Coco V; Caldarola G
G Ital Dermatol Venereol; 2013 Apr; 148(2):175-84. PubMed ID: 23588143
[TBL] [Abstract][Full Text] [Related]
70. Neutrophilic dermatoses: a review of current treatment options.
Cohen PR
Am J Clin Dermatol; 2009; 10(5):301-12. PubMed ID: 19658442
[TBL] [Abstract][Full Text] [Related]
71. A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
Falloon K; Cohen B; Ananthakrishnan AN; Barnes EL; Bhattacharya A; Colombel JF; Cross RK; Driscoll MS; Fernandez AP; Ha C; Herfarth H; Horst S; Hou J; Husni ME; Kroshinsky D; Kuhn KA; Lowder CY; Martin G; Parikh D; Sayed CJ; Schocket L; Siaton BC; Vedak P; Weisman MH; Rieder F
Aliment Pharmacol Ther; 2022 May; 55(9):1179-1191. PubMed ID: 35277863
[TBL] [Abstract][Full Text] [Related]
72. Comparison of Clinical Features between Pyoderma Gangrenosum Concomitant by Inflammatory Bowel Disease and Idiopathic Pyoderma Gangrenosum.
Jiang YY; Li J; Li Y; Wang Q; Liu S; Fang K; Qian JM; Jin HZ
Chin Med J (Engl); 2017 Nov; 130(22):2674-2679. PubMed ID: 29133754
[TBL] [Abstract][Full Text] [Related]
73. Investigation of new co-factors in 49 patients with pyoderma gangrenosum.
Al Ghazal P; Körber A; Klode J; Dissemond J
J Dtsch Dermatol Ges; 2012 Apr; 10(4):251-7. PubMed ID: 21762379
[TBL] [Abstract][Full Text] [Related]
74. Association of pyoderma gangrenosum, erythema nodosum and aseptic liver abscess without significant underlying disease.
Hanami Y; Mori T; Kikuchi N; Yamamoto T
Clin Exp Dermatol; 2019 Mar; 44(2):e16-e17. PubMed ID: 30460715
[No Abstract] [Full Text] [Related]
75. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients.
Mir-Madjlessi SH; Taylor JS; Farmer RG
Am J Gastroenterol; 1985 Aug; 80(8):615-20. PubMed ID: 4025277
[TBL] [Abstract][Full Text] [Related]
76. Do extraintestinal manifestations predict disease course, severity, and/or activity in IBD?
Walker D; Orchard T
Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S200-1. PubMed ID: 18816647
[No Abstract] [Full Text] [Related]
77. Extraintestinal manifestations in inflammatory bowel disease: Prevalence and predictors in Indian patients.
Bandyopadhyay D; Bandyopadhyay S; Ghosh P; De A; Bhattacharya A; Dhali GK; Das K
Indian J Gastroenterol; 2015 Sep; 34(5):387-94. PubMed ID: 26614005
[TBL] [Abstract][Full Text] [Related]
78. Management of peristomal pyoderma gangrenosum.
Poritz LS; Lebo MA; Bobb AD; Ardell CM; Koltun WA
J Am Coll Surg; 2008 Feb; 206(2):311-5. PubMed ID: 18222385
[TBL] [Abstract][Full Text] [Related]
79. Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013.
Barbosa NS; Tolkachjov SN; El-Azhary RA; Davis MD; Camilleri MJ; McEvoy MT; Bridges AG; Wetter DA
J Am Acad Dermatol; 2016 Nov; 75(5):931-939. PubMed ID: 27473454
[TBL] [Abstract][Full Text] [Related]
80. Pyoderma Gangrenosum and Erythema Nodosum Revealing Takayasu's Arteritis.
Loetscher J; Fistarol S; Walker UA
Case Rep Dermatol; 2016; 8(3):354-357. PubMed ID: 28101023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
